UK-based GW Pharmaceuticals has started a Phase II/III clinical trial of Epidiolex (cannabidiol or CBD) to treat Dravet syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy.

The Phase II/III trial is a two-part randomised double-blind, placebo-controlled parallel group safety, tolerability, pharmacokinetic and efficacy trial designed to evaluate single and multiple doses of Epidiolex in children with Dravet syndrome who are being treated with other anti-epileptic drugs.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Part one of the trial includes the pharmacokinetic and dose-finding elements in a total of 30 patients over a three-week treatment period, while the second part is a placebo-controlled safety and efficacy evaluation of Epidiolex over a three-month treatment period in a total of 80 patients.

The company said that all patients who complete the Phase II/III trial will be eligible to receive Epidiolex under a long-term open label extension trial.

"All patients who complete the Phase II/III trial will be eligible to receive Epidiolex under a long term open label extension trial."

NYU School of Medicine professor of Neurology, Neurosurgery, and Psychiatry and principal Investigator of the trial Orrin Devinsky said: "The results of our open-label trial of Epidiolex in children with Dravet syndrome have been very encouraging and we are excited to begin this important placebo-controlled clinical trial."

GW chief executive officer Justin Gover said: "Epidiolex is the first plant-based CBD medicine to be studied in a FDA-authorised, placebo-controlled trial and we look forward to working with leading paediatric epilepsy centres across the US to advance this clinical program as rapidly as possible."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

An additional Phase III trial in Dravet syndrome is expected to be started in the first quarter of 2015 in parallel with part two of the first Phase II/III trial.

In the first quarter of 2015, the company intends to begin two Phase III clinical trials in Lennox-Gastaut syndrome.

Clinical Trials Arena Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Clinical Trials Arena Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving clinical trials industry advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now